ArticleFrontiers in molecular neuroscience2025
Dysregulation of heterochromatin caused by genomic structural variants may be central to autism spectrum disorder.
Article in Frontiers in molecular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial.Human psychopharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autism spectrum disorder (ASD) is a highly heritable and heterogeneous neuropsychiatric condition whose cause is still unknown. A common function of proteins encoded by reported risk-genes for ASD is chromatin modification, but how this biological process relates to neurodevelopment and autism is unknown. We recently reported frequent genomic variants displaying Non-Mendelian inheritance (NMI) patterns in family trios in two cohorts of individuals with autism. These loci represent putative structural variants (SV) and the genes that carry them participate in neurodevelopment, glutamate signaling, and chromatin modification, confirming previous reports and providing greater detail for involvement of these processes in ASD. The majority of these loci were found in non-coding regions of the genome and were enriched for expression quantitative trait loci suggesting that gene dysregulation results from these genomic disruptions rather than alteration of proteins. Methods: Here, we intersected these putative ASD-associated SVs from our earlier work with diverse genome-wide gene regulatory and epigenetic multi-omic layers to identify statistically significant enrichments to understand how they may function to produce autism. Results: We find that these loci are enriched in dense heterochromatin and in transcription factor binding sites for SATB1, SRSF9, and NUP98-HOXA9. A model based on our results indicates that the core of ASD may reside in the dysregulation of a process analogous to RNA-induced Initiation of Transcriptional gene silencing that is meant to maintain heterochromatin. This produces SVs in the genes within these chromosomal regions, which also happen to be enriched for those involved in brain development and immune response. Discussion: This study mechanistically links previously reported ASD-risk genes involved in chromatin remodeling with neurodevelopment and may explain the role of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.